Published in J Mol Cell Cardiol on November 01, 1999
Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J Physiol (2004) 2.42
Reciprocal regulation of microRNA-1 and insulin-like growth factor-1 signal transduction cascade in cardiac and skeletal muscle in physiological and pathological conditions. Circulation (2009) 1.92
The gene expression fingerprint of human heart failure. Proc Natl Acad Sci U S A (2002) 1.73
Insulin-like growth factor 1 alleviates high-fat diet-induced myocardial contractile dysfunction: role of insulin signaling and mitochondrial function. Hypertension (2012) 1.66
Early beneficial effects of bone marrow-derived mesenchymal stem cells overexpressing Akt on cardiac metabolism after myocardial infarction. Stem Cells (2009) 1.50
Deletion of ribosomal S6 kinases does not attenuate pathological, physiological, or insulin-like growth factor 1 receptor-phosphoinositide 3-kinase-induced cardiac hypertrophy. Mol Cell Biol (2004) 1.43
Essential role of insulin and insulin-like growth factor 1 receptor signaling in cardiac development and function. Mol Cell Biol (2006) 1.34
Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategies. Vasc Health Risk Manag (2010) 1.24
Activation of extracellular signal-regulated kinase 5 reduces cardiac apoptosis and dysfunction via inhibition of a phosphodiesterase 3A/inducible cAMP early repressor feedback loop. Circ Res (2007) 1.16
A novel cardiomyocyte-enriched microRNA, miR-378, targets insulin-like growth factor 1 receptor: implications in postnatal cardiac remodeling and cell survival. J Biol Chem (2012) 1.12
IGF-1 expression in infarcted myocardium and MGF E peptide actions in rat cardiomyocytes in vitro. Mol Med (2009) 1.08
Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes (2015) 1.06
Deficiency of insulin-like growth factor 1 reduces sensitivity to aging-associated cardiomyocyte dysfunction. Rejuvenation Res (2008) 1.06
Chronic treatment with insulin-like growth factor I enhances myocyte contraction by upregulation of Akt-SERCA2a signaling pathway. Am J Physiol Heart Circ Physiol (2008) 1.05
The Impact of Overnutrition on Insulin Metabolic Signaling in the Heart and the Kidney. Cardiorenal Med (2011) 1.01
Cardiac overexpression of insulin-like growth factor 1 attenuates chronic alcohol intake-induced myocardial contractile dysfunction but not hypertrophy: Roles of Akt, mTOR, GSK3beta, and PTEN. Free Radic Biol Med (2010) 1.01
Simultaneous administration of insulin-like growth factor-1 and darbepoetin alfa protects the rat myocardium against myocardial infarction and enhances angiogenesis. Clin Transl Sci (2008) 1.00
Insulin-like growth factor 1 myocardial expression decreases in chronic alcohol consumption. Regen Med Res (2013) 0.97
Diabetes and the risk of heart failure. Heart Fail Clin (2011) 0.96
Sex differences in myocardial metabolism and cardiac function: an emerging concept. Pflugers Arch (2013) 0.92
FGF-16 is released from neonatal cardiac myocytes and alters growth-related signaling: a possible role in postnatal development. Am J Physiol Cell Physiol (2008) 0.92
Locally expressed IGF1 propeptide improves mouse heart function in induced dilated cardiomyopathy by blocking myocardial fibrosis and SRF-dependent CTGF induction. Dis Model Mech (2012) 0.91
Stem cell therapy: pieces of the puzzle. J Cardiovasc Transl Res (2009) 0.91
Menopause, the metabolic syndrome, and mind-body therapies. Menopause (2008) 0.90
Significantly increased risk of cardiovascular disease among patients with gallstone disease: a population-based cohort study. PLoS One (2013) 0.88
Effects of insulin-like growth factor-1 on the properties of mesenchymal stem cells in vitro. J Zhejiang Univ Sci B (2012) 0.87
Effects of short-term treadmill exercise training or growth hormone supplementation on diastolic function and exercise tolerance in old rats. J Gerontol A Biol Sci Med Sci (2008) 0.86
Increased myocardial SERCA expression in early type 2 diabetes mellitus is insulin dependent: In vivo and in vitro data. Cardiovasc Diabetol (2012) 0.86
Insulin-like growth factor I and II preserve myocardial structure in postinfarct swine. Heart (2001) 0.84
GH and the cardiovascular system: an update on a topic at heart. Endocrine (2014) 0.84
Overnutrition and the Cardiorenal Syndrome: Use of a Rodent Model to Examine Mechanisms. Cardiorenal Med (2011) 0.82
Attenuated cardiac mitochondrial-dependent apoptotic effects by li-fu formula in hamsters fed with a hypercholesterol diet. Evid Based Complement Alternat Med (2011) 0.80
A promoter polymorphism of the insulin-like growth factor-I gene is associated with left ventricular hypertrophy. Heart (2005) 0.79
Comparative endocrinology of aging and longevity regulation. Front Endocrinol (Lausanne) (2011) 0.79
Deficiency of insulin-like growth factor 1 reduces vulnerability to chronic alcohol intake-induced cardiomyocyte mechanical dysfunction: role of AMPK. J Cell Mol Med (2011) 0.78
Systemic acid load from the diet affects maximal-exercise RER. Med Sci Sports Exerc (2012) 0.77
Insulin-like growth factor I (IGF-1) deficiency ameliorates sex difference in cardiac contractile function and intracellular Ca(2+) homeostasis. Toxicol Lett (2011) 0.77
Doxorubicin impairs the insulin-like growth factor-1 system and causes insulin-like growth factor-1 resistance in cardiomyocytes. PLoS One (2015) 0.77
Cardiac insulin-like growth factor-1 and cyclins gene expression in canine models of ischemic or overpacing cardiomyopathy. BMC Cardiovasc Disord (2009) 0.77
Pharmacological Strategies to Retard Cardiovascular Aging. Circ Res (2016) 0.76
Prospective study of insulin-like growth factor-I, insulin-like growth factor-binding protein 3, genetic variants in the IGF1 and IGFBP3 genes and risk of coronary artery disease. Int J Mol Epidemiol Genet (2011) 0.75
Neonatal IGF-1/IGFBP-1 axis and retinopathy of prematurity are associated with increased blood pressure in preterm children. Acta Paediatr (2013) 0.75
TNF-α induces vascular insulin resistance via positive modulation of PTEN and decreased Akt/eNOS/NO signaling in high fat diet-fed mice. Cardiovasc Diabetol (2016) 0.75
Screening of growth hormone deficiency in short thalassaemic patients and effect of L-carnitine treatment. Arch Med Sci (2010) 0.75
Skeletal muscle inflammation and atrophy in heart failure. Heart Fail Rev (2017) 0.75
Serum IGF-I and hormonal responses to incremental exercise in athletes with and without left ventricular hypertrophy. J Sports Sci Med (2009) 0.75
Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation (1999) 8.04
Natriuretic peptides. N Engl J Med (1998) 6.04
Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA (1996) 4.03
Diabetes mellitus and hypertension. Hypertension (1992) 1.93
Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab (2001) 1.93
Altered platelet calcium metabolism as an early predictor of increased peripheral vascular resistance and preeclampsia in urban black women. N Engl J Med (1990) 1.80
Diabetes mellitus: a disease of abnormal cellular calcium metabolism? Am J Med (1994) 1.74
Clinical review 145: Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab (2002) 1.47
Plasma norepinephrine responses to posture and isometric exercise increase with age in the absence of obesity. J Gerontol (1983) 1.46
Leptin attenuates cardiac contraction in rat ventricular myocytes. Role of NO. Hypertension (2000) 1.42
Sex- and age-related antihypertensive effects of amlodipine. The Amlodipine Cardiovascular Community Trial Study Group. Am J Cardiol (1996) 1.41
Atrial natriuretic factor inhibits dehydration and hemorrhage-induced vasopressin release. Neuroendocrinology (1985) 1.36
A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med (1990) 1.35
Antihypertensive therapy and the risk of type 2 diabetes mellitus. N Engl J Med (2000) 1.27
Nesfatin-1 influences the excitability of paraventricular nucleus neurones. J Neuroendocrinol (2007) 1.24
Metoclopramide stimulates prolactin secretion in man. J Clin Endocrinol Metab (1976) 1.18
17 beta-Estradiol attenuates voltage-dependent Ca2+ currents in A7r5 vascular smooth muscle cell line. Am J Physiol (1994) 1.16
Atrial natriuretic factor inhibits dehydration- and angiotensin II-induced water intake in the conscious, unrestrained rat. Proc Natl Acad Sci U S A (1985) 1.14
Reduced contractile response to insulin and IGF-I in ventricular myocytes from genetically obese Zucker rats. Am J Physiol Heart Circ Physiol (2000) 1.10
Role of the sympathetic nervous system in blood pressure maintenance in obesity. J Clin Endocrinol Metab (1982) 1.09
Hypothalamic and pituitary sites of action of oxytocin to alter prolactin secretion in the rat. Endocrinology (1983) 1.07
Cost effectiveness of 24-hour ambulatory blood pressure monitoring in evaluation and treatment of essential hypertension. Am J Hypertens (1994) 1.06
Downregulation of K(+) channel genes expression in type I diabetic cardiomyopathy. Biochem Biophys Res Commun (2001) 1.04
Enhanced 24-hour norepinephrine and renin secretion in young patients with essential hypertension: relation with the circadian pattern of arterial blood pressure. Am J Cardiol (1985) 1.03
Acute airway obstruction due to a benign cervical goiter. Otolaryngol Head Neck Surg (1987) 1.02
Evidence for a physiological role for oxytocin in the control of prolactin secretion. Endocrinology (1986) 1.01
Central administration of atrial natriuretic factor inhibits saline preference in the rat. Endocrinology (1986) 1.00
Diabetes mellitus and diabetes-associated vascular disease. Trends Endocrinol Metab (2001) 1.00
Galanin: evidence for a hypothalamic site of action to release growth hormone. Peptides (1986) 0.99
Ambulatory blood pressure monitoring in a nonacademic setting. Effects of age and sex. Am J Hypertens (1992) 0.99
Effects of pioglitazone on calcium channels in vascular smooth muscle. Hypertension (1994) 0.99
Clinical review 91: Female sex hormones and cardiovascular disease in women. J Clin Endocrinol Metab (1997) 0.98
Altered inotropic response to IGF-I in diabetic rat heart: influence of intracellular Ca2+ and NO. Am J Physiol (1998) 0.97
Impairment of cardiopulmonary baroreflex after cardiac transplantation in humans. Circulation (1987) 0.97
Salt sensitivity and systemic hypertension in the elderly. Am J Cardiol (1988) 0.95
Insulin attenuates vasopressin-induced calcium transients and a voltage-dependent calcium response in rat vascular smooth muscle cells. J Clin Invest (1991) 0.95
Epidemiologic and clinical aspects of insulin resistance and hyperinsulinemia. Am J Med (1991) 0.95
The effect of fever on central alpha-MSH concentrations in the rabbit. Peptides (1981) 0.94
Evidence for a role of endogenous nesfatin-1 in the control of water drinking. J Neuroendocrinol (2012) 0.94
Central oxytocin inhibition of salt appetite in rats: evidence for differential sensing of plasma sodium and osmolality. Proc Natl Acad Sci U S A (1993) 0.94
Hyperpigmentation, vitiligo, and Addison's disease. Cutis (1985) 0.93
Dehydration-induced alterations in rat brain vasopressin and atrial natriuretic factor immunoreactivity. Endocrinology (1985) 0.93
Intrahypothalamic action of corticotrophin-releasing factor (CRF) to inhibit growth hormone and LH release in the rat. Life Sci (1984) 0.93
Metabolism of exogenous human chorionic gonadotrophin in men. J Endocrinol (1979) 0.93
Differential hypothalamic control of FSH secretion: a review. Psychoneuroendocrinology (1983) 0.92
Glucagon-like polypeptides in canine brain. Diabetes (1979) 0.92
Vasoactive intestinal peptide: evidence for a hypothalamic site of action to release growth hormone, luteinizing hormone, and prolactin in conscious ovariectomized rats. Endocrinology (1979) 0.91
Leydig cell tumor induced hypercalcemia in the Fischer rat: morphometric and histochemical evidence for a humoral factor that activates osteoclasts. Am J Pathol (1982) 0.90
Fever-specific changes in central MSH and CRF concentrations. Am J Physiol (1985) 0.90
In vitro stimulation of prolactin release by vasoactive intestinal peptide. Peptides (1980) 0.89
Cardiovascular disease in the diabetic woman. J Clin Endocrinol Metab (1999) 0.89
Tamoxifen (estrogen antagonist) inhibits voltage-gated calcium current and contractility in vascular smooth muscle from rats. J Pharmacol Exp Ther (1996) 0.89
Central oxytocin and ANP receptors mediate osmotic inhibition of salt appetite in rats. Am J Physiol (1995) 0.89
Neuropeptide Y affects secretion of luteinizing hormone and growth hormone in ovariectomized rats. Proc Natl Acad Sci U S A (1985) 0.89
Dopaminergic mediation of the natriuretic response to volume expansion. J Lab Clin Med (1985) 0.89
Hypertension symposium: newer topics on normal and abnormal blood pressure regulatory mechanisms. West J Med (1983) 0.89
Relative androgenicity, blood pressure levels, and cardiovascular risk factors in young healthy women. Am J Hypertens (1995) 0.88
Influence of age on contractile response to insulin-like growth factor 1 in ventricular myocytes from spontaneously hypertensive rats. Hypertension (1999) 0.88
Circadian variation in plasma dopamine levels in man. J Endocrinol Invest (1984) 0.88
Blood pressure and hormone changes associated with weight reduction in the obese. Hypertension (1982) 0.88
Neuropeptide W has cell phenotype-specific effects on the excitability of different subpopulations of paraventricular nucleus neurones. J Neuroendocrinol (2009) 0.88
Pathophysiology of male hypogonadism associated with endogenous hyperestrogenism. Evidence for dual defects in the gonadal axis. N Engl J Med (1985) 0.88
Troglitazone reduces contraction by inhibition of vascular smooth muscle cell Ca2+ currents and not endothelial nitric oxide production. Diabetes (1997) 0.88
Atrial natriuretic factor inhibits vasotocin-induced water reabsorption in the toad urinary bladder. Proc Soc Exp Biol Med (1986) 0.87
Effects of metformin on tyrosine kinase activity, glucose transport, and intracellular calcium in rat vascular smooth muscle. Endocrinology (1996) 0.87
Adrenal function following coronary bypass surgery. Am Heart J (1985) 0.87
Insulin potentiates platelet-derived growth factor action in vascular smooth muscle cells. Endocrinology (1998) 0.87
Gender differences in vascular compliance in young, healthy subjects assessed by pulse contour analysis. J Clin Hypertens (Greenwich) (2001) 0.86
Inhibition of Rho protein stimulates iNOS expression in rat vascular smooth muscle cells. Am J Physiol Heart Circ Physiol (2000) 0.86
Purification of FSH-releasing factor: its dissimilarity from LHRH of mammalian, avian, and piscian origin. Brain Res Bull (1987) 0.86
A novel reproductive peptide, phoenixin. J Neuroendocrinol (2013) 0.86
Effects of intraventricular growth hormone-releasing factor on growth hormone release: further evidence for ultrashort loop feedback. Endocrinology (1985) 0.86
Dopaminergic modulation of aldosterone secretion in man is unaffected by glucocorticoids and angiotensin blockade. J Clin Endocrinol Metab (1981) 0.86
Metformin but not glyburide prevents high glucose-induced abnormalities in relaxation and intracellular Ca2+ transients in adult rat ventricular myocytes. Diabetes (1999) 0.86
Chromatographic and biologic analysis of ME and OVLT LHRH. Peptides (1980) 0.86
Role of cellular calcium metabolism in abnormal glucose metabolism and diabetic hypertension. Am J Med (1989) 0.85
Comparison of metoclopramide with other dynamic tests of prolactin secretion. J Clin Endocrinol Metab (1976) 0.85
Calcium and protein kinase C mediate high-glucose-induced inhibition of inducible nitric oxide synthase in vascular smooth muscle cells. Hypertension (1998) 0.85
Effects of high calcium intake on blood pressure and calcium metabolism in young SHR. Hypertension (1984) 0.85
Altered dopaminergic modulation of sympathetic nervous system activity in idiopathic edema. J Endocrinol Invest (1984) 0.85
Insulin-like growth factor I diminishes in vivo and in vitro vascular contractility: role of vascular nitric oxide. Endocrinology (1996) 0.85
Reductions in plasma catecholamines and blood pressure during weight loss in obese subjects. Acta Endocrinol (Copenh) (1983) 0.85
Vascular insulin abnormalities, hypertension, and accelerated atherosclerosis. Am J Kidney Dis (1993) 0.84
Destruction of the dorsal anterior hypothalamic region suppresses pulsatile release of follicle stimulating hormone but not luteinizing hormone. Neuroendocrinology (1989) 0.84
Arginine vasopressin as a thyrotropin-releasing hormone. Science (1987) 0.84
An update on perioperative management of diabetes. Arch Intern Med (1999) 0.84
Dissociation of 24-hour catecholamine levels from blood pressure in older men. Hypertension (1986) 0.84
Reductions in total and extracellular water associated with calcium-induced natriuresis and the antihypertensive effect of calcium in blacks. Am J Hypertens (1988) 0.84
Hypertension in the elderly. Am J Med (1987) 0.84
Troglitazone attenuates high-glucose-induced abnormalities in relaxation and intracellular calcium in rat ventricular myocytes. Diabetes (1996) 0.84
Dopaminergic control of prolactin and blood pressure: altered control in essential hypertension. Hypertension (1982) 0.83
Dopaminergic modulation of renin release. Clin Exp Hypertens (1981) 0.83
Dopaminergic control of plasma catecholamine and aldosterone responses to acute stimuli in normal man. J Clin Endocrinol Metab (1980) 0.83
Dopaminergic regulation of natriuretic response to acute volume expansion in dogs. Clin Sci (Lond) (1985) 0.83
Growth hormone and prolactin secretion in Huntington's disease. Life Sci (1979) 0.83
Magnesium responsiveness to insulin and insulin-like growth factor I in erythrocytes from normotensive and hypertensive subjects. J Clin Endocrinol Metab (1998) 0.83
Effects of intravenous and intraventricular injection of antisera directed against corticotropin-releasing factor on the secretion of anterior pituitary hormones. Proc Natl Acad Sci U S A (1985) 0.83
Vasoactive intestinal peptide stimulates luteinizing hormone-releasing hormone release from median eminence synaptosomes. Regul Pept (1981) 0.83
In vivo and in vitro effects of cholecystokinin on gonadotropin, prolactin, growth hormone and thyrotropin release in the rat. Brain Res (1979) 0.83
Regulation of Na+,K(+)-ATPase gene expression by insulin in vascular smooth muscle cells. Am J Hypertens (1993) 0.82